No Data
No Data
CR Double-Crane Pharmaceutical Unit's Omeprazole Sodium for Injection Passes Regulatlry Evaluation
Double-Crane Pharma Gets China Clinical Trial Nod for Menstrual Dysfunction Drug
Double-Crane Pharma's Leukemia Medication Passes Generic Drug Evaluation in China
China Resources Double-Crane Pharmaceutical (600062.SH): ZP036 has obtained the Notice of Approval for Clinical Trial of Drugs.
On September 5th, C.R. Double-Crane Pharmaceutical (600062.SH) announced that its wholly-owned subsidiary, China Resources Purple Bamboo Pharmaceutical Co., Ltd. (referred to as "China Resources Purple Bamboo"), has received the "Drug Clinical Trial Approval Notice" (Notice Number: 2024LP02008) for ZP036 (referred to as "the pharmaceutical") issued by the National Medical Products Administration. ZP036 is used for the treatment of functional disorders caused by progesterone deficiency, including menstrual disorders, dysmenorrhea, premenstrual syndrome caused by ovulatory dysfunction, bleeding (caused by fibroids, etc.), premenopausal disorders, menopause (used for estrogen replacement therapy), and also helps with pregnancy.
China resources double-crane pharmaceutical (600062.SH): The consistency evaluation of generic drug quality and efficacy of Bixiaoan injection has been passed.
China Resources Double-Crane (600062.SH) announced that the company has received the National Medical Products Administration's approval notice for the supplementary application of Bai Xiao An Injection (referred to as "the pharmaceutical") (Notice Number: 2024B04014). Bai Xiao An Injection is used in combination with cyclophosphamide as a pre-transplant conditioning regimen for allogeneic hematopoietic stem cell transplantation in chronic myelogenous leukemia.
China Resources Double-Crane Pharmaceutical H1 Profit Up 6%, Operating Income Rises 1.5%
No Data